News

Potential Oral Treatment Reverses Advanced PAH in Rats, Study Shows

An orally available small molecule, BI113823, successfully reversed the progression of severe, advanced pulmonary arterial hypertension (PAH) in a rat model, a study demonstrated. The experimental medicine lowered pulmonary blood pressure, reduced blood vessel thickening, suppressed inflammatory responses, and prevented right heart failure and death. These findings support the…

Respiratory Procedure Eased Breathing in PAH, CTEPH Patients

Adults with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) who have trouble breathing at rest or with light activity may benefit from a procedure called respiratory rate modulation, a pilot, single-center study shows. The three-month procedure also led to lower symptom severity and decreased respiratory…

KER-012 Prevents Heart Damage in PH Mice

Treatment with the experimental medication KER-012 helped to prevent heart damage in a mouse model of pulmonary hypertension, new research shows. The findings were showcased by KER-012’s developer, Keros Therapeutics, at the American Heart Association (AHA) 2021 Scientific Sessions, held Nov. 13–15, according to a company press…

Yutrepia, Inhaled Treprostinil for PAH, Given Tentative Approval in US

The U.S. Food and Drug Administration (FDA) has granted tentative approval to Yutrepia (treprostinil), previously known as LIQ861, as an inhalation treatment for pulmonary arterial hypertension (PAH), its developer Liquidia announced. Tentative approval means that Yutrepia has met all regulatory standards regarding quality, safety, and efficacy required for approval in the U.S. Because…